CLGN
CollPlant Biotechnologies Ltd.
CLGN trails on the overall score without a compensating advantage in the available component scores.
OSCR
Oscar Health, Inc.
OSCR has the edge over CLGN overall, supported by stronger fundamentals.
CLGN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
CLGN's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CLGN PE Valuation
CLGN has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CLGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect CLGN's losses to shrink, with revenue declining.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CLGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$9.39 | +$1.91 |
| Q1 2026 | -$10.30 | +$1.90 |
| Q4 2025 | -$9.30 | +$5.30 |
| Q3 2025 | -$10.20 | +$5.10 |
| Q2 2025 | -$11.30 | +$4.00 |
| Q1 2025 | -$12.20 | -$5.50 |
| Q4 2024 | -$14.60 | -$8.10 |
| Q3 2024 | -$15.30 | -$9.20 |
CLGN is still losing money, but far less than before: $9.39 per share over the past year, against $21.40 at its worst in late 2019.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CLGN on earnings quality, reporting a profit while its opponent remains loss making.
CLGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $108K | -40% |
| Q1 2026 | $73K | -96% |
| Q4 2025 | $60K | -63% |
| Q3 2025 | $77K | +1825% |
| Q2 2025 | $179K | -28% |
| Q1 2025 | $2.1M | +1997% |
| Q4 2024 | $164K | -45% |
| Q3 2024 | $4K | -91% |
CLGN's revenue has slid since its 2021 peak: $108,000 last quarter, down 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2438% | -663 points |
| Q1 2026 | -4267% | -4187 points |
| Q4 2025 | -5250% | -2827 points |
| Q3 2025 | -4555% | +108995 points |
| Q2 2025 | -1775% | -5.9 points |
| Q1 2025 | -80% | +4337 points |
| Q4 2024 | -2423% | -728 points |
| Q3 2024 | -113550% | -102848 points |
CLGN's operating margin was −2438% last quarter, down 663 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CLGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CLGN on profitability, with a higher operating margin.
CLGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.5M | -$99K |
| Q1 2026 | -$3.1M | -$1.9M |
| Q4 2025 | -$3.2M | +$296.9K |
| Q3 2025 | -$2.9M | +$710K |
| Q2 2025 | -$2.4M | +$1.7M |
| Q1 2025 | -$1.2M | +$2.2M |
| Q4 2024 | -$3.5M | -$949K |
| Q3 2024 | -$3.6M | -155% |
CLGN has burned cash in almost every quarter: −$12M over the past year, against −$11M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CLGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
CLGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.9% | +67.9K shares |
| 1 year | +22% | +259K shares |
| 3 years | +22% | +265K shares |
| 5 years | +41% | +423K shares |
| Available history | +209% | +976K shares |
CLGN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
CLGN hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CLGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -9.1x | Net Cash |
| Q3 2021 | -11.9x | Net Cash |
| Q2 2021 | -2.5x | Net Cash |
| Q1 2021 | -2.5x | Net Cash |
CLGN has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CLGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.8 | Neutral |
| Stochastic | 23.1 | Neutral |
CLGN's weekly RSI is 50 (neutral) and its Stochastic is 23 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CLGN PE vs Healthcare Sector
CLGN has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CLGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.91 | 19% above |
| 20 week MA | $3.63 | 28% above |
| 50 week MA | $6.53 | 29% below |
| 100 week MA | $16.3 | 72% below |
| 200 week MA | $39.0 | 88% below |
CLGN has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 88% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CLGN on trend strength, trading above more of its moving averages.
CLGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.0 | $100.5 | +73% |
| 2021 | $100.5 | $132.2 | +32% |
| 2022 | $132.2 | $83.4 | -37% |
| 2023 | $83.4 | $63.9 | -23% |
| 2024 | $63.9 | $35.7 | -44% |
| 2025 | $35.7 | $15.3 | -57% |
| 2026 YTD | $15.3 | $4.64 | -70% |
CLGN has finished four years in a row lower, and it's down 70% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CLGN on returns for 2026, with the stronger performance.